Financial Insights Inc. Reduces Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Financial Insights Inc. lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 48.5% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,912 shares of the medical research company’s stock after selling 1,801 shares during the period. Financial Insights Inc.’s holdings in IQVIA were worth $453,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in IQV. Ballentine Partners LLC raised its stake in shares of IQVIA by 11.8% during the first quarter. Ballentine Partners LLC now owns 1,424 shares of the medical research company’s stock valued at $360,000 after purchasing an additional 150 shares during the period. Riverview Trust Co bought a new stake in shares of IQVIA in the first quarter worth $32,000. Wealth Enhancement Advisory Services LLC increased its stake in shares of IQVIA by 5.4% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 5,898 shares of the medical research company’s stock worth $1,492,000 after buying an additional 300 shares during the last quarter. Cypress Wealth Services LLC increased its stake in shares of IQVIA by 5.3% in the first quarter. Cypress Wealth Services LLC now owns 1,101 shares of the medical research company’s stock worth $278,000 after buying an additional 55 shares during the last quarter. Finally, Sendero Wealth Management LLC increased its stake in shares of IQVIA by 0.7% in the first quarter. Sendero Wealth Management LLC now owns 33,122 shares of the medical research company’s stock worth $8,376,000 after buying an additional 229 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

Shares of IQV opened at $228.30 on Wednesday. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The company has a market cap of $41.62 billion, a price-to-earnings ratio of 29.65, a price-to-earnings-growth ratio of 2.26 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The firm has a fifty day moving average of $238.87 and a 200-day moving average of $230.93.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.07. The business had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. IQVIA had a net margin of 9.39% and a return on equity of 28.59%. The company’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.22 earnings per share. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

Analysts Set New Price Targets

IQV has been the subject of a number of research analyst reports. Redburn Atlantic initiated coverage on shares of IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 price target for the company. Robert W. Baird boosted their target price on shares of IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a research note on Friday, September 20th. Argus upgraded shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Truist Financial lowered their target price on shares of IQVIA from $300.00 to $286.00 and set a “buy” rating for the company in a research note on Monday, October 14th. Finally, Jefferies Financial Group lowered shares of IQVIA from a “buy” rating to a “hold” rating and lowered their target price for the company from $266.00 to $242.00 in a research note on Wednesday, July 24th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $267.87.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.